News and Announcements
Bioactive Laboratories Pty Ltd FY15 Company Update
- Published January 29, 2015 3:46PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Bioactive Laboratories is on the brink of entering the market for its revolutionary stomach friendly anti-inflammatory & pain relieving agent. The largest pharmaceutical company in the sector joined in discussions late last year with the advancement of the TGA registration into its final phase. These strategic discussions centre on entering the $1b Aust complementary medicine market before distribution commences into its extensive export portfolio.
Managing Director, Rick Ferdinands, “This is a significant step forward. Together with the success of being invited into the new Federal Gov ‘Accelerating Commercialisation’ grants program, has given current investors something to smile about and new investors a clear incentive.”
Anti-inflammatory agents are the most widely used therapeutic agents globally. Millions worldwide suffer digestive, arthritic and skin based inflammatory conditions which are all on the rise. Bioactive Laboratories have identified a gap in the market for a safe plant based alternative to side effect prone NSAIDs (Non-Steroidal Anti-inflammatory Drugs). The target market in vitamin and supplements is worth $68Billion annually.
Please click on the ‘Receive Offer’ button below for more information or to register your interest.
ABOUT BIOACTIVE LABORATORIES PTY LTD
Bioactive Laboratories specialises in plant based solutions for human health.
They have developed the first anti-inflammatory and pain relieving agent that is gentle to the stomach. Studies show it rivals the drug efficacy and strength of NSAIDs[1] such as Voltaren, without digestive side effects.
Global market sectors worth an estimated $560Billion[2] annually make anti-inflammatories & pain agents the most widely used of all drugs and complementary medicines.
A faster route to market exists, than traditional biotech via the booming Complementary Medicine market to supply bulk powders & extracts.
Profitability within four years is predicted via a conservative financial model. This hybrid complementary medicine/drug development business model, suggests self funding for the development pipeline that includes drug candidates & revolutionary plant based solutions for type-2 diabetes.
Customers such as pharmaceutical & complementary medicine companies have been approached and are anxious to gain access.
[1] NSAIDs: Non-Steroidal Anti-Inflammatory Drugs
[2] $560Billion: Includes 3 major inflammatory health market sectors: Digestive diseases (US market $141Billion in 2004), Arthritis/Rheumatic (US market $128Billion in 2003), and Skin (global market $292Billion annually by 2015).
Company Updates
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
Backed By Leading Investment Groups and Family Offices
